Company: SUPN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0001356576-25-000017
Chunk: 216

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 8
Chunk 216
---
,423 Employee taxes paid related to net share settlement of equity awards(2,715)(1,990)— Payment of contingent consideration— — (22,900)Net cash provided by (used in) financing activities12,193 (397,880)(10,477)Net change in cash and cash equivalents(5,723)(18,066)(110,314)Cash and cash equivalents at beginning of year75,054 93,120 203,434 Cash and cash equivalents at end of year$69,331 $75,054 $93,120 Supplemental cash flow informationCash paid for income taxes$53,254 $36,602 $16,200 Cash paid for interest on debt$— $1,946 $2,516 Noncash investing and financing activitiesProperty and equipment additions from utilization of tenant improvement allowance— — $580 

See accompanying notes.

96